STAT

The coronavirus gives Trump his biggest outbreak emergency yet — and experts are worried

The #coronavirus offers President Trump a major test, and veterans of other disease outbreaks and epidemics are worried about how he’ll handle it.
CDC Director Robert Redfield (second right) and Anthony Fauci (right), the director of National Institute of Allergy and Infectious Diseases, brief senators on the coronavirus.

WASHINGTON — When Ebola was spreading in West Africa in 2014, Donald Trump took to Twitter.

“STOP THE FLIGHTS!,” he blasted in all capital letters. “NO VISAS FROM EBOLA STRICKEN COUNTRIES.”

He even cast doubt on the honesty of the Centers for Disease Control and Prevention, tweeting: “Ebola is much easier to transmit than the CDC and government representatives are admitting. Spreading all over Africa — and fast.”

It wasn’t true, of course, and common wisdom among public health authorities holds that blocking flights does nothing to stop the spread of disease. It can, in some cases, make things worse.

Now Trump is president, and leading an administration that is chaotic and fractious. The outbreak of a new coronavirus could be his biggest public health challenge, and veterans of other disease outbreaks and epidemics are worried about how he’ll handle it.

“We are likely to see trade bans, quarantines and other overreactions that are very harmful,” said Lawrence Gostin, a senior professor at Georgetown University and an expert in global health law who has advised several administrations. “With the Ebola epidemic, it was urging

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks